Georgia Registration Variations: Type I and Type II Changes

1. Key takeaways

The statutory framework for registration variations in Georgia is a two-tier system: Article 11¹¹ of the Law of Georgia on Drugs and Pharmaceutical Activity, Law No. 1586 of August 10, 2009, lists Type I and Type II variations. The industry-standard three-tier classification — Type IA, Type IB, and Type II — is a further subdivision of Type I and is a practical estimate without explicit statutory basis. Under industry practice, the corresponding timelines are approximately 20 days for Type IA, approximately 1 month for Type IB, and a fresh application treated like a first registration for Type II.

The gap between the statutory two tiers and the practical three tiers is the central risk of variation management in Georgia. The authority reviews against the statutory framework, while the applicant grades against the practical framework. Unless the filing bridges the two explicitly — stating the statutory classification first and the practical subdivision second — every variation carries a latent reclassification risk that can change the procedure, the cost, and the timeline without warning.

The practical grading matrix must therefore be built on statutory logic first. The question that decides the tier is not how much engineering effort the change consumed, but whether the change affects safety and performance; only after that statutory test is answered does the practical IA/IB/II subdivision apply as a scheduling and pricing tool. Filing templates should hard-code this order of reasoning, so no variation leaves the regulatory function without both layers of classification. When the statutory and practical gradings point in different directions, the statutory tier always governs the procedure actually followed.

2. Legal basis

The variation framework rests on the following provisions.

1. Law of Georgia on Drugs and Pharmaceutical Activity, Law No. 1586 of August 10, 2009, consolidated version of November 30, 2023: Article 11¹¹ — national registration under the national regime, including Type I and Type II variations.
2. The same article also covers: re-registration, validity of registration, registration documentation requirements, registration fees, suspension and revocation of registration.
3. Article 11⁶ (Article 116): entry in the sectoral registry and maintenance of registry information.
4. Article 11⁵ paragraph 1: the validity of a marketing authorisation is determined under the two regimes.
5. Practical estimate statement: the three-tier IA/IB/II classification and the approximately 20-day and 1-month timelines are not stated in any official legal text and derive from established industry practice.

The consolidated version of November 30, 2023, is the operative text for variation work, and Article 11⁶ plays a larger role here than in first registrations, because every approved variation must be mirrored in the registry information for the certificate to remain internally consistent.

3. Expert insights

Insight 1: the gap between two statutory tiers and three practical tiers is the biggest risk point of variation management. Manufacturers grade changes under the practical IA/IB/II scheme, but the authority reviews against the two-tier framework of the statute. When a grading dispute arises, the only citable basis is Article 11¹¹. The filing should therefore open with the statutory characterisation — stating that the change is a Type I variation under Article 11¹¹ — and only then present the practical subdivision and its reasoning. This two-layer presentation gives the reviewer a statutory anchor while preserving the internal grading discipline of the manufacturer.

Insight 2: a Type II variation filed as a fresh application means a step change in cost. Under the practical estimate, Type II changes require a new application with the requirements of a first registration — this is not a supplementary submission but a full procedural restart. Product iteration planning must therefore forecast which engineering changes will cross the Type II threshold and keep changes within the Type I range wherever technically possible. A change that can be split into smaller increments should be split; a change that cannot should be scheduled against a new-registration budget, not a variation budget.

Insight 3: variation approval and registry update must proceed in step. Article 11⁶ requires the registry information to reflect the actual situation. If the registry record is not updated after a variation is approved, the certificate and the registry diverge, and the inconsistency surfaces at customs clearance or in tender documents — precisely where discrepancies attract the most scrutiny. The registry update should be a gated step of the variation workflow, not an administrative afterthought.

4. Practical recommendations

The following practices operationalise the two-tier statutory frame and the three-tier practical frame.

1. Build a variation grading matrix: assess first whether the change affects safety and performance to determine the statutory tier, then apply the practical three-tier subdivision, and record both determinations with their reasoning in the change file.
2. Open every submission with the statutory characterisation in the first paragraph and the practical subdivision rationale in the second, keeping the two layers clearly separated so the reviewer can cite the statutory basis directly.
3. Move product iteration planning upstream into the development stage, splitting or deferring any change likely to trigger a Type II filing, and document that assessment before the change is implemented.
4. Complete the registry information update within 15 working days of variation approval and retain proof of the synchronisation in the change file.
5. Archive the authority response to each variation alongside the grading reasoning, building a precedent library that makes the next grading decision faster and better evidenced.

Manufacturers running multi-model portfolios should maintain one grading matrix per product family rather than one per project, because the same physical change — a new material supplier, a software version, a labelling update — recurs across models and the grading reasoning should be consistent family-wide. Inconsistent grading of identical changes across models is itself a review finding.

5. Verification checklist

• □ Variation grading matrix established and reviewed by the regulatory function
• □ Submissions contain the statutory characterisation plus the practical subdivision in two paragraphs
• □ Type II trigger risk assessed at the development stage
• □ Registry information synchronised after approval
• □ Consistency between variation and first-registration documentation checked

Regulatory information verified as of October 30, 2026

This English version was prepared by GRZAN for the international medical device registration guide. GRZAN provides regulatory translation, dossier preparation and market-entry support for Georgia and other jurisdictions. Questions about this article may be sent to info@grzanglobal.com.